Open access
Aug 2026
Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.
A multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM), finding post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy was 15% versus 85% for detectable versu...
Patrick Gould, D. Coskey, Xin Ma et al.
· Haematologica · 0 citations